Open AccessEML4‐ALK Rearrangement and Its Therapeutic Implications in Inflammatory Myofibroblastic Tumors
Author(s) -
VargasMadueno Fernando,
Gould Edwin,
Valor Raul,
Ngo Nhu,
Zhang Linsheng,
VillalonaCalero Miguel A.
Publication year - 2018
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2018-0014
Subject(s) - medicine , targeted therapy , precision medicine , tyrosine kinase , nilotinib , cancer research , anaplastic lymphoma kinase , imatinib , myeloid leukemia , oncology , pathology , cancer , lung cancer , receptor , malignant pleural effusion
With the advent of precision medicine, medical oncology is undergoing a transcendental change. These molecular studies have allowed us to learn about potential targeted therapies for patients with advanced cancers. Perhaps the best‐known example of success in precision medicine is chronic myeloid leukemia and its response to tyrosine kinase inhibitors targeting the BCR‐ABL kinase. Since that original discovery, the role of molecular therapeutics has expanded, and it now presents us with treatment options for common malignancies and rare atypical tumors. In this article, we present a case of a 61‐year‐old female with a recurrent pulmonary inflammatory myofibroblastic tumor. Subsequent molecular studies revealed an ALK rearrangement. The significance of this alteration in this tumor type and its therapeutic implications are discussed herein. Key Points This case exemplifies the heterogeneous behavior of inflammatory myofibroblastic tumors (IMTs) and the current role of targeted therapy in the therapeutic armamentarium of neoplastic processes. As evidenced by the different mutations found in IMTs, it is of great importance to perform next‐generation sequencing in uncommon neoplasms. These studies can find different potential targets and therapeutic options for patients devoid of standard effective therapies.